GlassScriptPhysician profile
Suchitra Koneru
NPI 1336170729
$13,225.66
in general payments reported to CMS, 2019-2025
44 companies · $2,494 in 2025
The $2,494 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,822 · 2020: $1,472 · 2021: $1,685 · 2022: $1,899 · 2023: $1,949 · 2024: $1,904 · 2025: $2,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,301 · Education: $46.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,301.07 |
| Education | $46.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,565.95 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,371.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,182.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $803.72 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Pfizer INC. | $776.74 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $767.63 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $631.93 | 2019-2022 | |
| Abbvie INC. | $629.27 | 2021-2024 | |
| Glaxosmithkline, LLC. | $613.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $530.97 | 2019-2025 | Repatha, Repatha, Otezla |
| Corcept Therapeutics | $379.37 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $305.07 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $294.22 | 2019-2023 | Seglentis, Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $277.47 | 2022-2025 | |
| Amarin Pharma, INC. | $272.44 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suchitra Koneru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.